RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Deepwise, a Beijing-Hangzhou AI-based medical imaging diagnostics company, has completed a Series C round of undisclosed size. In three previous fundings, Deepwise raised $43 million. Formerly known as the AI Lab Project of Peking University, Deepwise was spun out of PU in 2017. The company’s products are now used in 200 China hospitals. Deepwise said its success is due in part to its academic and scientific network. The C round was led by Sunshine Insurance Group, Changfazhan, SRHC and the Sunland Fund.
Source: China Biotoday
